POINT Biopharma Global Inc. , a company engaged in  the discovery, development, and global access to life-changing radiopharmaceuticals, recently announced details of the initial clinical trial in the Company’s pan-cancer Fibroblast Activation Protein-α (FAP-α) targeted program PNT2004, FRONTIER.

The Phase 1 clinical trial is expected to commence in the summer of 2022 in Canada and will use a gallium-68 (68Ga)-based PNT6555 molecular imaging agent to select patients to receive a no-carrier-added (n.c.a.) lutetium-177 (177Lu)-based PNT6555 therapeutic agent. The Phase 1 clinical protocol will evaluate PNT6555 in ~30 patients in five FAP-avid cancer indications: colorectal, pancreatic, esophageal, melanoma, and soft tissue sarcoma.

To read more please visit:

POINT Biopharma Unveils FRONTIER: A Pan-Cancer FAP-α Targeted Clinical Program

Source: POINT